Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine
2. Azd6094
3. Hmpl-504
4. Volitinib
1. Volitinib
2. 1313725-88-0
3. Azd-6094
4. Hmpl-504
5. Azd6094
6. Savolitinib [inn]
7. Hmpl504
8. (s)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-[1,2,3]triazolo[4,5-b]pyrazine
9. Chembl3334567
10. 2a2da6857r
11. 1h-1,2,3-triazolo(4,5-b)pyrazine, 1-((1s)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1h-pyrazol-4-yl)-
12. 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
13. Orpathys
14. Unii-2a2da6857r
15. Azd6094, Hmpl-504
16. Volitinib(savolitinib)
17. Azd-6094volitinib
18. Savolitinib (usan/inn)
19. Savolitinib [usan:inn]
20. Savolitinib [usan]
21. Savolitinib [who-dd]
22. Gtpl9918
23. Hmpl 504
24. Schembl12489208
25. Ex-a845
26. Dtxsid801111016
27. Azd 6094
28. Bdbm50023342
29. Mfcd28359096
30. Nsc782121
31. Nsc800966
32. S7674
33. Akos030526403
34. Savolitinib(azd6094, Hmpl-504)
35. Zinc149738712
36. Ccg-267976
37. Db12048
38. Nsc-782121
39. Nsc-800966
40. Compound 28 [pmid: 25148209]
41. Ncgc00475727-01
42. Ac-35267
43. As-35250
44. Bv160378
45. Hy-15959
46. Savolitinib;volitinib;hmpl-504;azd-6094
47. A14419
48. D11139
49. J-690125
50. Q27254463
51. (3e)-5-chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2h-indol-2-one Hydrochloride
52. 1-((s)-1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)-triazolo(4,5-b)pyrazine
53. 4-{1-[(1s)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1h-pyrazole
| Molecular Weight | 345.4 g/mol |
|---|---|
| Molecular Formula | C17H15N9 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 345.14504152 g/mol |
| Monoisotopic Mass | 345.14504152 g/mol |
| Topological Polar Surface Area | 91.6 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 505 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of lung cancer
Treatment of renal neoplasms
Drugs in Development
Details:
Orpathys (savolitinib) in combination with Tagrisso (osimertinib) is approved for the treatment of advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 30, 2025
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED gets China Nod for ORPATHYS Plus TAGRISSO in Lung Cancer Treatment
Details : Orpathys (savolitinib) in combination with Tagrisso (osimertinib) is approved for the treatment of advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2025
Details:
HMPL-504 (savolitinib) is an oral, potent, and highly selective MET tyrosine kinase inhibitor, being developed for gastric cancer.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Brand Name: HMPL-504
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2025
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Finishes Enrollment for Savolitinib Gastric Cancer Phase 2 Trial
Details : HMPL-504 (savolitinib) is an oral, potent, and highly selective MET tyrosine kinase inhibitor, being developed for gastric cancer.
Product Name : HMPL-504
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2025
Details:
Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is approved for MET exon 14 skipping altered NSCLC.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2025
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Announces Full Approval for ORPATHYS® in MET Exon 14 NSCLC
Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is approved for MET exon 14 skipping altered NSCLC.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2025
Details:
Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 01, 2025
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED NDA Acceptance in China for ORPATHYS® & TAGRISSO® Lung Cancer
Details : Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 01, 2025
Details:
Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO®
Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Details:
Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAGRISSO® and ORPATHYS® Show High Response in MET-Positive Lung Cancer in SAVANNAH Study
Details : Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.
Product Name : Tagrisso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2024
Details:
Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is indicated for patients with non-small cell lung cancer with MET exon 14 skipping alterations.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2024
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED’s Savolitinib sNDA Accepted in China for Treatment-Naïve Metastatic NSCLC
Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is indicated for patients with non-small cell lung cancer with MET exon 14 skipping alterations.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2024
Details:
Orpathys (savolitinib), is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2023
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Details : Orpathys (savolitinib), is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2023
Details:
ORPATHYS® (savolitinib), an oral, potent and highly selective MET tyrosine kinase inhibitor, has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic NSCLC adult patients with MET exon 14-skipping alterations.
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: National Healthcare Security Administration
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2023
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : National Healthcare Security Administration
Deal Size : Undisclosed
Deal Type : Agreement
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement D...
Details : ORPATHYS® (savolitinib), an oral, potent and highly selective MET tyrosine kinase inhibitor, has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic NSCLC adult patients with MET exon 14-skip...
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 18, 2023
Details:
Preliminary results from SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an ORR of 49% in patients with epidermal growth factor receptor-mutated NSCLC with high levels of mesenchymal epithelial transition overexpression.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: AstraZeneca
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2022
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Resp...
Details : Preliminary results from SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an ORR of 49% in patients with epidermal growth factor receptor-mutated NSCLC with high levels of mesenchymal epithelial transition overex...
Product Name : Tagrisso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
19
PharmaCompass offers a list of Savolitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Savolitinib manufacturer or Savolitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Savolitinib manufacturer or Savolitinib supplier.
PharmaCompass also assists you with knowing the Savolitinib API Price utilized in the formulation of products. Savolitinib API Price is not always fixed or binding as the Savolitinib Price is obtained through a variety of data sources. The Savolitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Savolitinib;Volitinib;HMPL-504;AZD-6094 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Savolitinib;Volitinib;HMPL-504;AZD-6094, including repackagers and relabelers. The FDA regulates Savolitinib;Volitinib;HMPL-504;AZD-6094 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Savolitinib;Volitinib;HMPL-504;AZD-6094 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Savolitinib;Volitinib;HMPL-504;AZD-6094 supplier is an individual or a company that provides Savolitinib;Volitinib;HMPL-504;AZD-6094 active pharmaceutical ingredient (API) or Savolitinib;Volitinib;HMPL-504;AZD-6094 finished formulations upon request. The Savolitinib;Volitinib;HMPL-504;AZD-6094 suppliers may include Savolitinib;Volitinib;HMPL-504;AZD-6094 API manufacturers, exporters, distributors and traders.
Savolitinib;Volitinib;HMPL-504;AZD-6094 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Savolitinib;Volitinib;HMPL-504;AZD-6094 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Savolitinib;Volitinib;HMPL-504;AZD-6094 GMP manufacturer or Savolitinib;Volitinib;HMPL-504;AZD-6094 GMP API supplier for your needs.
A Savolitinib;Volitinib;HMPL-504;AZD-6094 CoA (Certificate of Analysis) is a formal document that attests to Savolitinib;Volitinib;HMPL-504;AZD-6094's compliance with Savolitinib;Volitinib;HMPL-504;AZD-6094 specifications and serves as a tool for batch-level quality control.
Savolitinib;Volitinib;HMPL-504;AZD-6094 CoA mostly includes findings from lab analyses of a specific batch. For each Savolitinib;Volitinib;HMPL-504;AZD-6094 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Savolitinib;Volitinib;HMPL-504;AZD-6094 may be tested according to a variety of international standards, such as European Pharmacopoeia (Savolitinib;Volitinib;HMPL-504;AZD-6094 EP), Savolitinib;Volitinib;HMPL-504;AZD-6094 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Savolitinib;Volitinib;HMPL-504;AZD-6094 USP).
